May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Autologous Serum in the Treatment of Vernal Keratoconjunctivitis
Author Affiliations & Notes
  • J. P. Ramirez
    Cornea, Fundacion Hospital Nuestra Senora de La Luz I.A.P., Mexico Distrito Federal, Mexico
  • R. Velasco
    Cornea, Fundacion Hospital Nuestra Senora de La Luz I.A.P., Mexico Distrito Federal, Mexico
  • O. Baca
    Cornea, Fundacion Hospital Nuestra Senora de La Luz I.A.P., Mexico Distrito Federal, Mexico
  • A. Babayan
    Cornea, Fundacion Hospital Nuestra Senora de La Luz I.A.P., Mexico Distrito Federal, Mexico
  • Footnotes
    Commercial Relationships  J.P. Ramirez, None; R. Velasco, None; O. Baca, None; A. Babayan, None.
  • Footnotes
    Support  4284
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4743. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. P. Ramirez, R. Velasco, O. Baca, A. Babayan; Autologous Serum in the Treatment of Vernal Keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4743. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the clinical response with autologous serum treatment in patients with vernal keratoconjunctivitis.

Methods: : This is a longitudinal, prospective and experimental study of cases with vernal keratoconjunctivitis refractive to conventional treatment. Patients were treated with topical autologous serum at 20% every 4 hours. Clinical symptoms and signs were reported before treatment and every week with autologous serum drops. We designed a questionnaire and photographic guide to evaluate treatment response in each patient objectively. Follow up study was one month.

Results: : We included 20 eyes of 10 patients with vernal keratoconjunctivits, with a mean average of 9.4 years old 8 were male and 2 were female. The response to treatment with autologous serum was a decrease of 78.13% of the symptoms and 66.27% percent of signs at one month follow up. No adverse effects were presented.

Conclusions: : Autologous serum can be an alternative treatment in vernal keratoconjunctivitis with important decrease of signs and symptoms without adverse effects of conventional therapies.

Keywords: cornea: clinical science • conjunctivitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×